Read Gene

Read Gene Depreciation & Amortization

The Depreciation & Amortization of Read Gene (RDG.WA) as of Nov 6, 2026 is 451,100.00 PLN. In the previous year, Depreciation & Amortization was 482,300.00 PLN — a change of -6.47% (lower).

Depreciation & Amortization

451,100.00PLN

YoY

-6.47%

Last updated:

Depreciation & Amortization of Read Gene is 2025 451,100.00 PLN. Depreciation & Amortization of Read Gene was 2024 482,300.00 PLN. It decreases by -6.47% lower compared to the previous year.

The Read Gene Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2018
1.30 M PLN
Jan 1, 2019
1.47 M PLN
Jan 1, 2020
651,100.00 PLN
Jan 1, 2021
560,200.00 PLN
Jan 1, 2022
456,000.00 PLN
Jan 1, 2023
492,400.00 PLN
Jan 1, 2024
482,300.00 PLN
Jan 1, 2025
451,100.00 PLN
The Read Gene Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
451,100.00PLN-6.47%
482,300.00PLN-2.05%
492,400.00PLN+7.98%
456,000.00PLN-18.60%
560,200.00PLN-13.96%
651,100.00PLN-55.70%
1.47 MPLN+13.39%
1.30 MPLN+4.69%
1.24 MPLN+10.41%
1.12 MPLN-33.85%
1.70 MPLN+173.42%
620,000.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Depreciation & Amortization of Read Gene is 451,100.00 PLN in 2025.

Depreciation & Amortization of Read Gene changed from 482,300.00 PLN to 451,100.00 PLN, representing a -6.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization Read Gene since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's Read Gene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Read Gene

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Read Gene